Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Semaglutide marketed by Novo Nordisk under NDC Code 0169-4136-11 NDC Code(s) : 0169-4136-11, 0169-4136-02, 0169-4132-90, 0169-4132-97, 0169-4132-11, 0169-4132-12, 0169-4130-01, 0169-4130-13, 0169-4772-11, 0169-4772-12, 0169-4772-90, 0169-4772-97, 0169-4181-03, 0169-4181-13, 0169-4181-90, 0169-4181-97 Packager : Novo Nordisk Category : HUMAN PRESCRIPTION DRUG LABEL DEA Schedule : none Marketing Status : New Drug Application INGREDIENTS AND APPEARANCE LABELER - Novo Nordisk(622920320) PRINCIPAL DISPLAY PANEL 0.25 mg 0.5 mg NDC 0169-4181-13List 418113 OZEMPIC (semaglutide) injection For Single Patient Use Only 2 mg/3 mL (0.68 mg/mL) Prefilled pen Pen delivers doses in 0.25 mg or 0.5 mg increments only For subcutaneous use only Use OZEMPIC once weekly Contains: 1 OZEMPIC pen, 6 NovoFine Plus 32G needles, Product Literature
The 0.01 mg/kg dose that showed consistent effects in rats translates to approximately 0.0016 to 0.004 mg/kg in humans, which works out to roughly 0.112 to 0.28 mg for a 154-pound person
Telemedicine consultations at Hormone Fitness can help you determine if Tirzepatide is the right fit for your weight loss journey
The Lancet, 397 (10278), 971984
Control of Appetite: Semaglutides effects on the brains areas responsible for controlling appetite help in controlling food cravings and desires
